Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Alcoholic Cirrhosis

sorafenib has been researched along with Alcoholic Cirrhosis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chen, B; Cheng, J; Lei, J; Li, Y; Lu, Y; Safadi, R; Si, T; Wu, T; Yang, X; Zhang, L; Zhang, R1
Fehér, J; Lengyel, G1

Reviews

1 review(s) available for sorafenib and Alcoholic Cirrhosis

ArticleYear
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
    Orvosi hetilap, 2010, Jun-06, Volume: 151, Issue:23

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper; Developed Countries; Developing Countries; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Iron; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Neoplasms; Metabolic Diseases; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Smoking; Sorafenib

2010

Other Studies

1 other study(ies) available for sorafenib and Alcoholic Cirrhosis

ArticleYear
Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study.
    Drug design, development and therapy, 2022, Volume: 16

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Neoplasms; Phenylurea Compounds; Quinolines; Retrospective Studies; Risk Factors; Sorafenib

2022